
    
      The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined
      with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver
      mutation non- squamous non-small cell lung cancer .According to the result of TAX317,the ORR
      of second line standard chemotherapy was 5- 8%. We expect the ORR was 20%. Using PASS11, we
      calculated the sample size of this study was 39 , according to 10% censoring,the expected
      sample size is 43.
    
  